Francois Habersetzer

Summary

Country: France

Publications

  1. ncbi A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C
    Francois Habersetzer
    INSERM, Strasbourg, France Université de Strasbourg, Strasbourg, France
    Gastroenterology 141:890-899.e1-4. 2011
  2. ncbi Challenges for HCV vaccine development in HIV-HCV coinfection
    Mélanie Lambotin
    INSERM, U748, 67000 Strasbourg, France
    Expert Rev Vaccines 11:791-804. 2012
  3. ncbi GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection
    Francois Habersetzer
    Hopitaux Universitaires de Strasbourg, Service d Hepatogastroenterologie, Strasbourg, France
    Curr Opin Mol Ther 11:456-62. 2009

Collaborators

Detail Information

Publications3

  1. ncbi A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C
    Francois Habersetzer
    INSERM, Strasbourg, France Université de Strasbourg, Strasbourg, France
    Gastroenterology 141:890-899.e1-4. 2011
    ..We performed a phase I clinical trial to assess the safety, immunogenicity, and early antiviral efficacy of TG4040 in patients with CHC...
  2. ncbi Challenges for HCV vaccine development in HIV-HCV coinfection
    Mélanie Lambotin
    INSERM, U748, 67000 Strasbourg, France
    Expert Rev Vaccines 11:791-804. 2012
    ..Here, the authors review the pathogenesis of hepatitis C in HIV-infected patients, with a focus on the impact of HIV on HCV-specific immune responses and discuss the challenges for vaccine development in HIV-HCV coinfection...
  3. ncbi GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection
    Francois Habersetzer
    Hopitaux Universitaires de Strasbourg, Service d Hepatogastroenterologie, Strasbourg, France
    Curr Opin Mol Ther 11:456-62. 2009
    ....